

Chunze Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6657446/publications.pdf>

Version: 2024-02-01

30
papers

441
citations

687363

13
h-index

794594

19
g-index

32
all docs

32
docs citations

32
times ranked

480
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetic and exposureâ€“response analysis for trastuzumab administered using a subcutaneous â€œmanual syringeâ€“injection or intravenously in women with HER2-positive early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 77-88.	2.3	52
2	Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates. <i>Clinical Pharmacokinetics</i> , 2015, 54, 81-93.	3.5	36
3	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 82, 1-13.	2.7	33
4	Confounding factors in exposureâ€“response analyses and mitigation strategies for monoclonal antibodies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2493-2501.	2.4	25
5	Modelâ€“informed Therapeutic Dose Optimization Strategies for Antibodyâ€“Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administrationâ€“Approved Antibodyâ€“Drug Conjugates?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1216-1230.	4.7	25
6	Integrated Twoâ€“Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Nonâ€“Hodgkin Lymphoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 48-59.	2.5	23
7	Clinical pharmacology of vc-MMAE antibodyâ€“drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. <i>MAbs</i> , 2020, 12, 1699768.	5.2	21
8	Population pharmacokinetics and exposureâ€“response of trastuzumab emtansine in advanced breast cancer previously treated with â‰¥2 HER2â€“targeted regimens. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2767-2777.	2.4	18
9	Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2905-2914.	1.3	18
10	Exposureâ€“response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1079-1090.	2.3	17
11	Strategies and Recommendations for Using a Dataâ€“Driven and Riskâ€“Based Approach in the Selection of Firstâ€“inâ€“Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1395-1416.	4.7	17
12	Prediction of Human Pharmacokinetics of Antibodyâ€“Drug Conjugates From Nonclinical Data. <i>Clinical and Translational Science</i> , 2019, 12, 534-544.	3.1	16
13	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory. <i>Pharmaceutical Research</i> , 2018, 35, 122.	3.5	13
14	A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1069-1080.	3.5	12
15	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 831-842.	2.3	12
16	Ethnic sensitivity assessment of the antibodyâ€“drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 547-558.	2.3	11
17	Clinical pharmacology strategies in supporting drug development and approval of antibodyâ€“drug conjugates in oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 743-765.	2.3	11
18	Exposureâ€“safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 646-646.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 537-548.	1.8	9
20	Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S120-S131.	2.0	9
21	Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S105-S119.	2.0	8
22	Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 606-615.	2.5	7
23	Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma. , 2014, , .		7
24	Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 754-769.	4.7	7
25	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. <i>Pharmaceutical Research</i> , 2020, 37, 252.	3.5	6
26	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 347-359.	2.3	4
27	Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 499-512.	2.3	4
28	Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 175-185.	2.3	3
29	Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1096-1105.	2.0	2
30	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2019, , 151-190.		0